Attruby (acoramidis) ATTR-CM program
approveddrug program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat symptomatic transthyretin amyloid cardiomyopathy by stabilizing transthyretin and reducing amyloid formation in the heart.
Oral acoramidis TTR stabilizer evaluated in randomized phase 3 ATTRibute-CM, open-label extensions, and subgroup analyses in wild-type and variant ATTR-CM.
Published 2026 ATTRibute-CM and open-label extension analyses reporting efficacy in wild-type and variant ATTR-CM; site lists Attruby as a medicine.
Acoramidis showed clinical benefit in ATTRibute-CM. In one 2026 analysis, acoramidis reduced risk of all-cause mortality/first cardiovascular hospitalization at month 30 in ATTRwt-CM and ATTRv-CM and reduced all-cause mortality through month 42.
BBO-11818 pan-KRAS inhibitor program
phase 1drug program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat KRAS-mutant cancers, including clinically significant KRAS mutants such as KRASG12D and KRASG12V.
Potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor targeting multiple KRAS mutants in both inactive GDP-bound and active GTP-bound states.
2026 publication states BBO-11818 entered phase I clinical trials for patients with various KRAS mutations in colorectal, pancreatic, and lung cancers.
Preclinical studies reported inhibition of MAPK signaling and cellular viability in KRAS-driven lines, tumor regressions in KRAS-mutant xenograft models, and enhanced efficacy in combinations with anti-PD-1, anti-EGFR antibodies, and a RAS:PI3Kalpha breaker compound.
ACT-EARLY acoramidis ATTR prevention program
phase 3drug program · high · Sat Nov 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Determine whether acoramidis can prevent or delay ATTR-CM or ATTR-PN in asymptomatic adults carrying pathogenic TTR variants.
Clinical prevention study in asymptomatic TTR variant carriers, using acoramidis to bind and stabilize TTR before symptomatic disease develops.
ACT-EARLY clinical trial record published in 2025; related open-label extension for newly diagnosed ATTR-CM or ATTR-CM plus ATTR-PN listed in 2025.
Acoramidis ATTR-PN program
phase 3drug program · high · Wed Sep 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate acoramidis for symptomatic transthyretin amyloid polyneuropathy.
Phase 3 efficacy and safety clinical trial of acoramidis in subjects with symptomatic ATTR-PN.
Phase 3 ATTRibute-PN trial record published in 2021, with an earlier related AG10 ATTR-PN study record pointing to the updated design.
Acoramidis modified-release formulation program
phase 1drug program · medium · Sun Mar 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate pharmacokinetics of modified-release acoramidis formulations in healthy subjects.
Single-center, open-label, 5-period pharmacokinetic study in healthy male and non-pregnant, non-lactating healthy female subjects.
Clinical trial record published in 2021 for single-dose pharmacokinetic evaluation of acoramidis modified-release formulations.
NULIBRY (fosdenopterin) medicine program
approveddrug program · medium
Provide a listed BridgeBio medicine for a rare genetic disease context described on the company site.
Fosdenopterin medicine listed among BridgeBio medicines in the supplied site analysis.
Listed by the company site analysis as a BridgeBio medicine.
